RT Book, Section A1 Papadakis, Maxine A. A1 McPhee, Stephen J. A1 Rabow, Michael W. A1 McQuaid, Kenneth R. SR Print(0) ID 1183884699 T1 Cancer T2 Current Medical Diagnosis & Treatment 2022 YR 2022 FD 2022 PB McGraw-Hill Education PP New York, NY SN 9781264269389 LK accessmedicine.mhmedical.com/content.aspx?aid=1183884699 RD 2024/03/28 AB ROS1-rearranged lung cancers respond to crizotinib (ALK, cMET, and ROS1 tyrosine kinase inhibitor) and entrectinib (multikinase inhibitor, including ROS-1) with response rates over 70%.